MX2021012939A - Formulaciones de factor ix liofilizadas. - Google Patents

Formulaciones de factor ix liofilizadas.

Info

Publication number
MX2021012939A
MX2021012939A MX2021012939A MX2021012939A MX2021012939A MX 2021012939 A MX2021012939 A MX 2021012939A MX 2021012939 A MX2021012939 A MX 2021012939A MX 2021012939 A MX2021012939 A MX 2021012939A MX 2021012939 A MX2021012939 A MX 2021012939A
Authority
MX
Mexico
Prior art keywords
fix
polypeptide
formulations
present
factor
Prior art date
Application number
MX2021012939A
Other languages
English (en)
Inventor
Brian M Thome
Cherie Parkhurst-Lang
Brandon W Leveille
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021012939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2021012939A publication Critical patent/MX2021012939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención provee, entre otras cosas, formulaciones pre-liofilización, formulaciones reconstituidas y formulaciones de polvo liofilizado que comprenden un polipéptido de Factor IX (FIX). La presente invención proporciona también métodos de liofilización para producir un polvo liofilizado que comprende un polipéptido de FIX. La presente invención se refiere a una formulación pre-liofilización que comprende: (a) un polipéptido (FIX) de Factor IX que tiene actividad de coagulación FIX; (b) un agente amortiguador; (c) un agente estabilizante; (d) un agente espesante; y (e) un tensioactivo, donde la formulación tiene un volumen de relleno menor que alrededor de 5 L y donde cada uno de (a)-(e) se encuentran en una cantidad por vial (mg/vial) suficiente para permitir (1) mejor estabilidad del polipéptido de FIX al liofilizarse.
MX2021012939A 2014-03-24 2016-09-23 Formulaciones de factor ix liofilizadas. MX2021012939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24

Publications (1)

Publication Number Publication Date
MX2021012939A true MX2021012939A (es) 2021-11-25

Family

ID=54196282

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012447A MX2016012447A (es) 2014-03-24 2015-03-24 Formulaciones de factor ix liofilizadas.
MX2021012939A MX2021012939A (es) 2014-03-24 2016-09-23 Formulaciones de factor ix liofilizadas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016012447A MX2016012447A (es) 2014-03-24 2015-03-24 Formulaciones de factor ix liofilizadas.

Country Status (16)

Country Link
US (2) US10772942B2 (es)
EP (1) EP3123090A4 (es)
JP (4) JP7058940B2 (es)
KR (1) KR102385372B1 (es)
AR (1) AR099838A1 (es)
AU (3) AU2015236340B2 (es)
CA (1) CA2943034C (es)
CL (1) CL2016002386A1 (es)
EA (2) EA202092926A3 (es)
IL (3) IL247869B (es)
MA (1) MA39779A (es)
MX (2) MX2016012447A (es)
PH (1) PH12016501877A1 (es)
SG (3) SG10201913735SA (es)
TW (1) TWI700101B (es)
WO (1) WO2015148444A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505926VA (en) * 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
TWI700101B (zh) 2014-03-24 2020-08-01 美商百歐維拉提夫治療公司 凍乾之因子ｉｘ調配物
WO2019014338A1 (en) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. METHOD FOR PRESERVING BIOPHARMACEUTICAL PRODUCTS
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
BR112022015272A2 (pt) 2020-02-04 2022-09-20 Regeneron Pharma Teor de umidade residual alvo para produto de fármaco liofilizado
WO2021231319A1 (en) * 2020-05-11 2021-11-18 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (es) * 1996-10-16 2000-09-09 Alza Corp
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
CA2383144A1 (en) * 1999-09-17 2001-03-29 Takeda Chemical Industries, Ltd. Process for producing protein powder
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
WO2005089712A1 (en) 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
SI3130601T1 (sl) 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
CA2625998C (en) * 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
NZ567685A (en) 2005-11-01 2011-07-29 Wyeth Corp A Factor IX formulation for injection comprising sodium chloride
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
SI2628746T1 (sl) 2006-04-04 2019-04-30 Chiesi Farmaceutici S.P.A. Proces za koncentriranje polipeptida
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
JP5613876B2 (ja) 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 延長された半減期を備えるヒト第ｉｘ因子変異体
US20090176708A1 (en) 2007-12-27 2009-07-09 Peter Turecek Chemically modified factor ix
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
KR20110005862A (ko) 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
JP5785077B2 (ja) 2008-08-05 2015-09-24 ワイス・エルエルシー 崩壊温度より高温での凍結乾燥
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
NZ605348A (en) * 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EP2672986B1 (en) 2011-02-09 2020-03-18 GlaxoSmithKline LLC Lyophilized formulations
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
SG11201505926VA (en) * 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
TWI700101B (zh) * 2014-03-24 2020-08-01 美商百歐維拉提夫治療公司 凍乾之因子ｉｘ調配物

Also Published As

Publication number Publication date
EA038573B1 (ru) 2021-09-16
MA39779A (fr) 2017-02-01
MX2016012447A (es) 2017-01-06
AU2022215218A1 (en) 2022-09-01
EA202092926A2 (ru) 2021-07-30
TW201605492A (zh) 2016-02-16
BR112016021777A2 (pt) 2017-10-03
JP2022044689A (ja) 2022-03-17
CA2943034A1 (en) 2015-10-01
SG11201607642RA (en) 2016-10-28
JP7503583B2 (ja) 2024-06-20
WO2015148444A1 (en) 2015-10-01
US10772942B2 (en) 2020-09-15
CL2016002386A1 (es) 2017-06-23
JP2020063313A (ja) 2020-04-23
IL247869A0 (en) 2016-11-30
KR20160137577A (ko) 2016-11-30
SG10201913735SA (en) 2020-03-30
AU2015236340B2 (en) 2020-02-06
JP2017510585A (ja) 2017-04-13
US20210069307A1 (en) 2021-03-11
IL281197A (en) 2021-04-29
EA201691807A1 (ru) 2017-03-31
NZ724351A (en) 2023-10-27
TWI700101B (zh) 2020-08-01
US20170173122A1 (en) 2017-06-22
AU2020202863A1 (en) 2020-05-21
SG10201808249VA (en) 2018-10-30
AR099838A1 (es) 2016-08-24
IL247869B (en) 2020-02-27
EP3123090A4 (en) 2017-12-13
AU2020202863B2 (en) 2022-09-01
PH12016501877A1 (en) 2016-12-19
AU2015236340A1 (en) 2016-09-29
EP3123090A1 (en) 2017-02-01
JP2024053015A (ja) 2024-04-12
IL281197B (en) 2022-06-01
JP7058940B2 (ja) 2022-04-25
IL272257B (en) 2021-03-25
KR102385372B1 (ko) 2022-04-11
IL272257A (en) 2020-02-27
EA202092926A3 (ru) 2021-10-29
CA2943034C (en) 2022-06-14

Similar Documents

Publication Publication Date Title
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX2016000739A (es) Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
EP4378959A3 (en) Formulation for anti-alpha4beta7 antibody
EA200870264A1 (ru) Композиция антител
PH12019550084A1 (en) Oligosaccharides for flavour generation
WO2015058173A8 (en) Stable solid units and methods of making the same
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
TW200630118A (en) Stabilized freeze-dried formulation for cephalosporin derivatives
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
PH12018500458A1 (en) Vlp stabilized vaccine compositions
SA520412281B1 (ar) Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
MX2016012870A (es) Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
EA201390206A1 (ru) Составы для бычьего гранулоцитарного колониестимулирующего фактора и его вариантов
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY